If you’ve walked into Walker Pharmacy in the last six months and not heard someone ask about weight loss medications, I’d be surprised. GLP-1 receptor agonists — the class of drugs that includes Ozempic, Wegovy, and Zepbound — have dominated health conversations for the past two years. And this month, the landscape shifted again with two major developments that patients across Statesboro, Bulloch County, and Southeast Georgia are asking about.

On April 1, the FDA approved Foundayo (orforglipron), a new GLP-1 pill from Eli Lilly that doesn’t require the injections many patients dread. Then, just days later, a Stanford University study revealed that roughly one in ten people may be genetically resistant to GLP-1 medications altogether. Let’s break down what the research actually says — and what it means at the pharmacy counter.

A GLP-1 Pill You Can Take Any Time of Day

Foundayo is the second oral GLP-1 medication to reach the U.S. market, but it comes with a significant practical advantage. Unlike the oral semaglutide pill (Rybelsus), which must be taken first thing in the morning on an empty stomach with only a small sip of water, Foundayo can be taken at any time of day without food or water restrictions (Eli Lilly press release, April 1, 2026).

In Lilly’s Phase 3 ATTAIN-1 clinical trial, adults with obesity who took the highest dose of orforglipron for 72 weeks lost an average of 12.4% of their body weight (about 27 pounds), compared with 0.9% for those on placebo (Drugs.com). The approval was notable for its speed — Foundayo was the first new molecular entity approved under the FDA’s Commissioner’s National Priority Voucher program, and it received the fastest approval of a new molecular entity since 2002.

The most commonly reported side effects in trials included nausea (up to 35% of participants), constipation, diarrhea, vomiting, and indigestion. Most gastrointestinal side effects were mild to moderate and tended to improve as patients adjusted to the medication. Pricing through Eli Lilly’s LillyDirect program starts at $149 per month for the lowest dose for self-pay patients, with commercially insured patients potentially paying as little as $25 per month.

Not Everyone Responds the Same Way: The GLP-1 Resistance Study

Just ten days after Foundayo’s approval, a study published April 10 in the journal Genome Medicine from researchers at Stanford University added an important layer of nuance to the GLP-1 conversation. The decade-long international study found that approximately 10% of the general population carries genetic variants that may make GLP-1 medications less effective for them (Stanford Medicine, April 2026).

The researchers identified two specific genetic variants that impair an enzyme called PAM (peptidyl-glycine alpha-amidating monooxygenase), which plays a unique role in activating several hormones in the body, including GLP-1. People carrying these variants appear to produce higher levels of GLP-1 naturally but respond less effectively to the hormone — a phenomenon the researchers call “GLP-1 resistance.”

In a combined analysis of three clinical trials involving 1,119 participants, individuals with PAM variants were less likely to reach target blood sugar (HbA1c) levels after six months of GLP-1 treatment. About 25% of participants without the variants met the recommended HbA1c target, compared with just 11.5% of those with the p.S539W variant and 18.5% of those with the p.D563G variant (ScienceDaily, April 11, 2026).

It’s important to note that this study focused specifically on blood sugar regulation in diabetes patients — not weight loss outcomes. The researchers acknowledged they have not yet identified the exact mechanism behind this resistance, and more studies are needed.

The FDA Is Still Watching Closely

On April 14, the FDA asked Eli Lilly to provide additional post-marketing safety data on Foundayo, including long-term studies on cardiovascular events, delayed gastric emptying, effects on breast milk, and thyroid cancer risk over at least 15 years (CNBC, April 14, 2026). This is standard practice for newly approved medications — the FDA routinely requires post-marketing studies to build a more complete safety profile. It does not mean a safety problem has been found, but it’s a reminder that these medications are still relatively new, and the full picture of their long-term effects is still developing.

A Pharmacist’s Perspective

Here’s what I’d tell you if you walked up to my counter at Walker Pharmacy and asked about all of this:

The arrival of oral GLP-1 options is genuinely significant for patients who need these medications but are uncomfortable with injections. That’s a real barrier for some folks, and removing it matters. At the same time, I want to be straightforward: a 12.4% average weight loss over 72 weeks is meaningful, but it is less than what the injectable options have shown in their trials. Different medications work differently for different people, and the “best” option depends on your individual health profile, not on headlines.

The GLP-1 resistance research is fascinating, but I’d caution against reading too much into it right now. A study showing that genetic variants affect blood sugar response in diabetes patients doesn’t necessarily tell us how those same variants affect weight loss outcomes. This is early-stage science — important, but not something that should change anyone’s treatment decisions today.

What I am encouraged by is the trend toward more options and better pricing. Competition between manufacturers is bringing costs down, and that’s good news for the many patients in our community who could benefit from these medications but have been priced out.

As always, the most important step is having an honest conversation with your doctor or pharmacist about whether any of these medications are appropriate for your specific situation. There is no one-size-fits-all answer here.

Frequently Asked Questions

Is Foundayo the same as Ozempic in pill form?

No. Foundayo (orforglipron) is a different medication from Ozempic (semaglutide), though both belong to the GLP-1 receptor agonist class. They work through a similar mechanism but are different molecules made by different manufacturers — Foundayo by Eli Lilly and Ozempic by Novo Nordisk. Foundayo’s main practical advantage is that it can be taken at any time of day without food or water restrictions.

Should I get genetic testing to see if GLP-1 drugs will work for me?

At this point, genetic testing for GLP-1 resistance is not part of standard clinical practice. The Stanford study is an important step in understanding why these medications work better for some people than others, but the research is still in its early stages. If you’re considering a GLP-1 medication, the best approach is to work with your healthcare provider to monitor how you respond to treatment and adjust your plan accordingly.

How much does the new GLP-1 pill cost?

Foundayo’s list price has not been widely published, but Eli Lilly has announced self-pay pricing through their LillyDirect program starting at $149 per month for the lowest dose. Commercially insured patients may pay as little as $25 per month with eligible coverage. Medicare Part D beneficiaries may be able to access Foundayo for $50 per month beginning as early as July 2026. Your actual cost will depend on your insurance plan and coverage.

Are GLP-1 pills as effective as the injections?

Based on current clinical trial data, the injectable GLP-1 medications have generally shown greater average weight loss than the oral formulations. Foundayo’s trials showed an average of 12.4% body weight loss over 72 weeks, while injectable semaglutide (Wegovy) trials showed approximately 15-17% and tirzepatide (Zepbound) showed up to 22%. However, individual results vary significantly, and effectiveness is just one factor — convenience, tolerability, and cost all play roles in finding the right treatment for each patient.

Can I get Foundayo at Walker Pharmacy?

We are working to have Foundayo available through our pharmacies as distribution expands. In the meantime, if you have questions about GLP-1 medications or want to discuss your options, stop by any of our four locations in Statesboro, Brooklet, or Lyons. We’re always happy to help you understand your choices — no appointment needed.

Talk to Your Pharmacist

The world of weight management medications is changing fast, and it can be hard to separate the science from the hype. That’s exactly what your local pharmacist is here for. Whether you have questions about a new medication, want to understand your current prescriptions better, or are thinking about making a change, we’re here to help at Walker Pharmacy.

Transfer your prescriptions to Walker Pharmacy and let us be your partner in health.

This article is for informational purposes only and does not constitute medical or health advice. Always consult your physician or pharmacist before making changes to your health regimen.

— Jordan Walker, PharmD | Owner, Walker Pharmacy